Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk

Area of Science:

• Cardiology
• Rheumatology
• Immunology

Background:

• Cardiac involvement is a significant complication of primary systemic vasculitides.
• Both the disease process and its treatments can affect the heart.
• Systemic vasculitis patients face an elevated risk of cardiovascular events.

Purpose of the Study:

• To review cardiac involvement across various primary systemic vasculitides.
• To discuss the impact of vasculitis on cardiac health.
• To examine the cardiovascular risks associated with vasculitis treatments.

Main Methods:

• Literature review of primary systemic vasculitides with cardiac manifestations.
• Analysis of specific vasculitis types: anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), Kawasaki's disease (KD), Takayasu's arteritis, and Behcet's disease.
• Evaluation of the cardiovascular effects of common vasculitis therapies.

Main Results:

• Eosinophilic granulomatosis with polyangiitis (a form of AAV) frequently involves the heart, worsening prognosis.
• Kawasaki's disease commonly causes coronary artery aneurysms, leading to premature ischemic heart disease.
• Takayasu's arteritis and Behcet's disease present with distinct cardiac issues like aortic incompetence, myocarditis, or intracardiac masses.
• Corticosteroids increase myocardial infarction risk, while other agents may reduce cardiovascular events by reducing inflammation.

Conclusions:

• Cardiac involvement significantly worsens outcomes in primary systemic vasculitis.
• Specific vasculitides have characteristic cardiac manifestations.
• Therapeutic strategies must consider and mitigate cardiovascular risks.
• Enhanced awareness and management of modifiable cardiovascular risk factors are crucial for these patients.